T1	p 6 46	Recurrent epithelial ovarian carcinoma :
T2	p 233 373	patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy . PATIENTS AND
T3	p 382 434	Patients with measurable and assessable disease were
T4	p 718 764	of 474 patients were treated ( 239 PLD and 235
T5	p 1889 1909	patient population .
T6	i 79 129	pegylated liposomal doxorubicin versus topotecan .
T7	i 176 229	pegylated liposomal doxorubicin ( PLD ) and topotecan
T8	i 346 358	chemotherapy
T9	i 464 481	PLD 50 mg/m ( 2 )
T10	i 487 538	1-hour infusion every 4 weeks or topotecan 1.5 mg/m
T11	i 753 756	PLD
T12	i 765 776	topotecan )
T13	i 958 967	topotecan
T14	i 1068 1071	PLD
T15	i 1091 1100	topotecan
T16	i 1202 1205	PLD
T17	i 1275 1278	PLD
T18	i 1301 1310	topotecan
T19	i 1370 1379	topotecan
T20	i 1545 1554	topotecan
T21	i 1618 1627	topotecan
T22	i 1846 1849	PLD
T23	o 153 172	efficacy and safety
T24	o 831 870	overall progression-free survival rates
T25	o 923 967	overall response rates for PLD and topotecan
T26	o 1020 1049	Median overall survival times
T27	o 1206 1235	for progression-free survival
T28	o 1317 1339	overall survival , PLD
T29	o 1489 1526	nonstatistically significant survival
T30	o 1569 1596	Severe hematologic toxicity
T31	o 1670 1739	dosage modification , or growth factor or blood product utilization .
T32	o 1766 1774	efficacy
T33	o 1777 1801	favorable safety profile